Quantcast

Latest Uric acid Stories

2011-05-25 15:45:00

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK. Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination...

2011-05-19 07:30:00

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and...

2011-05-17 10:00:00

CLEVELAND, May 17, 2011 /PRNewswire/ -- A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans.(1) Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly...

2011-05-04 17:23:00

EAST BRUNSWICK, N.J., May 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that it has, through its wholly owned subsidiary, Savient Pharma Ireland Limited, delivered via courier to the European Medicines Agency (EMA) and the assigned co-rapporteurs, the Marketing Authorization Application (MAA) for KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Currently there are no EMA...

2011-05-02 12:32:08

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC. Gout is caused by the deposition of monosodium urate (MSU) monohydrate crystals that stimulate acute episodes of inflammation. Chronic tophaceous gout often presents as juxtarticular soft-tissue masses, distinct erosions, overhanging bony margins, and thickening...

2011-04-28 15:05:00

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress. The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation. The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe...

2011-04-25 08:00:00

SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional data from its completed Phase 2b study (Study 203) evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) on May 26, 2011 in London, UK. The Company will also present additional data from a...

2011-04-06 09:15:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling. Gout is also associated with other serious health conditions, making it a complex diagnosis and treatment challenge for physicians. In addition to the core patient demographic of men age 40 plus, post-menopausal women are at...

2011-02-28 06:30:00

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period. Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of either 160 milligrams (mg) or 80...

2011-01-18 15:27:56

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center. Osteoarthritis is a debilitating joint degeneration for which no drug has been proven to slow or halt its progression. Physicians can only offer to treat the symptoms associated with osteoarthritis, and people with the condition are often subject to a reduced quality of life. "Finding a way to...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related